AALL2131
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT06124157 ↗
- Recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built an HCP commentary report on AALL2131 (blinatumomab plus dasatinib; blinatumomab plus imatinib in newly-diagnosed Ph+ or ABL-class Ph-like B-ALL) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on AALL2131 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- B Acute Lymphoblastic Leukemia
- Interventions
- Biospecimen Collection; Blinatumomab; Bone Marrow Biopsy; Calaspargase Pegol; Cyclophosphamide; Cytarabine; Dasatinib; Daunorubicin; Doxorubicin; Echocardiography Test; Imatinib; Leucovorin; Mercaptopurine; Methotrexate; Multigated Acquisition Scan; Pegaspargase; Prednisolone; Prednisone; Radiation Therapy; Thioguanine; Vincristine
- Arms
- Stratum I (Ph+ ALL) · Experimental
- Stratum II (PDGFRB ABL-Class fusions) · Experimental
- Stratum III (non-PDGFRB ABL-Class fusions) · Experimental
- Enrollment
- 222 (estimated)
- Primary outcomes
- Philadelphia chromosome-positive (Ph+) (BCR::ABL1-rearranged) 3-year event free survival (EFS)
- ABL-class Ph-like B-ALL 3-year event free survival (EFS)
- Incidence of adverse events
- Sponsor
- National Cancer Institute (NCI)
- Start
- May 30, 2025
- Primary completion
- Dec 1, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT06124157 · updated Oct 27, 2026